Patents by Inventor Lisa Rojkjaer

Lisa Rojkjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS AND USES THEREOF
    Publication number: 20200353077
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • COMBINATIONS AND USES THEREOF
    Publication number: 20200352975
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide
    Patent number: 10308722
    Abstract: The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: June 4, 2019
    Assignee: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • METHOD FOR THE TREATMENT OF MULTIPLE MYELOMA OR NON-HODGKINS LYMPHOMA WITH ANTI-CD38 ANTIBODY AND BORTEZOMIB OR CARFILZOMIB
    Publication number: 20180022823
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: August 7, 2017
    Publication date: January 25, 2018
    Inventors: LISA ROJKJAER, RAINER BOXHAMMER, JAN ENDELL, MARK WINDERLICH, CHRISTOFER SAMUELSSON
  • Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib
    Patent number: 9765152
    Abstract: A method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody and bortezomib or carfilzomib is disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 19, 2017
    Assignee: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Combinations and uses thereof
    Patent number: 9579378
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: February 28, 2017
    Assignee: MORPHOSYS AG
    Inventors: Jan Endell, Lisa Rojkjaer
  • Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
    Publication number: 20160222127
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 4, 2016
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Combinations and uses thereof
    Patent number: 9289490
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: March 22, 2016
    Assignee: MorphoSys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • COMBINATIONS AND USES THEREOF
    Publication number: 20150238603
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.
    Type: Application
    Filed: September 24, 2013
    Publication date: August 27, 2015
    Applicant: MORPHOSYS AG
    Inventors: Jan Endell, Lisa Rojkjaer
  • COMBINATIONS AND USES THEREOF
    Publication number: 20150017160
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Applicant: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
    Patent number: 8877899
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: November 4, 2014
    Assignee: Morphosys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD
    Publication number: 20140255427
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: September 11, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Combination therapy with an anti-CD19 antibody and a purine analog
    Publication number: 20140227277
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 14, 2012
    Publication date: August 14, 2014
    Applicant: MorphoSys AG
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
    Publication number: 20130302318
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: September 26, 2011
    Publication date: November 14, 2013
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • METHOD OF TREATMENT OF HEREDITARY HEMOCHROMATOSIS
    Publication number: 20110294861
    Abstract: The present invention relates to the use of Compound I of the following formula in the treatment of iron overload resulting from hereditary hemochromatosis in patient in need of such a treatment and to a commercial package comprising Compound I together with instructions for the treatment of iron overload in hereditary hemochromatosis patients.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 1, 2011
    Applicant: NOVARTIS AG
    Inventors: Hanspeter Nick, Lisa Rojkjaer, Janet Ellen Bodner, Peter Wayne Marks
  • METHOD OF TREATMENT OF HEREDITARY HEMOCHROMATOSIS
    Publication number: 20110105575
    Abstract: The present invention relates to the use of Compound I of the following formula in the treatment of iron overload resulting from hereditary hemochromatosis in patient in need of such a treatment and to a commercial package comprising Compound I together with instructions for the treatment of iron overload in hereditary hemochromatosis patients.
    Type: Application
    Filed: May 21, 2007
    Publication date: May 5, 2011
    Inventors: Hanspeter Nick, Lisa Rojkjaer, Janet Ellen Bodner, Peter Wayne Marks
  • Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
    Publication number: 20050032690
    Abstract: The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.
    Type: Application
    Filed: December 17, 2003
    Publication date: February 10, 2005
    Inventors: Lisa Rojkjaer, Marie Johannessen, Ole Nordfang, Jens Jansen